248 related articles for article (PubMed ID: 19546299)
1. eComment: A comparison of the safety of aprotinin and tranexamic acid in cardiac surgery.
Koniari I; Apostolakis E; Mandellou M
Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):101. PubMed ID: 19546299
[No Abstract] [Full Text] [Related]
2. Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.
Takagi H; Manabe H; Kawai N; Goto SN; Umemoto T
Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):98-101. PubMed ID: 19380335
[TBL] [Abstract][Full Text] [Related]
3. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
[TBL] [Abstract][Full Text] [Related]
4. The post-BART anti-fibrinolytic dilemma?
Beattie WS; Karkouti K
J Cardiothorac Vasc Anesth; 2011 Feb; 25(1):3-5. PubMed ID: 21272775
[No Abstract] [Full Text] [Related]
5. Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies.
Ngaage DL; Bland JM
Eur J Cardiothorac Surg; 2010 Jun; 37(6):1375-83. PubMed ID: 20117944
[TBL] [Abstract][Full Text] [Related]
6. Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin.
Howell N; Senanayake E; Freemantle N; Pagano D
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):234-40. PubMed ID: 22889481
[TBL] [Abstract][Full Text] [Related]
7. ε-Aminocaproic acid and clinical value in cardiac anesthesia.
Raghunathan K; Connelly NR; Kanter GJ
J Cardiothorac Vasc Anesth; 2011 Feb; 25(1):16-9. PubMed ID: 20870423
[TBL] [Abstract][Full Text] [Related]
8. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.
Later AF; Maas JJ; Engbers FH; Versteegh MI; Bruggemans EF; Dion RA; Klautz RJ
Eur J Cardiothorac Surg; 2009 Aug; 36(2):322-9. PubMed ID: 19250838
[TBL] [Abstract][Full Text] [Related]
9. The risk associated with aprotinin in cardiac surgery.
Mangano DT; Tudor IC; Dietzel C; ;
N Engl J Med; 2006 Jan; 354(4):353-65. PubMed ID: 16436767
[TBL] [Abstract][Full Text] [Related]
10. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
Fergusson DA; Hébert PC; Mazer CD; Fremes S; MacAdams C; Murkin JM; Teoh K; Duke PC; Arellano R; Blajchman MA; Bussières JS; Côté D; Karski J; Martineau R; Robblee JA; Rodger M; Wells G; Clinch J; Pretorius R;
N Engl J Med; 2008 May; 358(22):2319-31. PubMed ID: 18480196
[TBL] [Abstract][Full Text] [Related]
11. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.
Martin K; Wiesner G; Breuer T; Lange R; Tassani P
Anesth Analg; 2008 Dec; 107(6):1783-90. PubMed ID: 19020118
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
Levi M; Cromheecke ME; de Jonge E; Prins MH; de Mol BJ; Briët E; Büller HR
Lancet; 1999 Dec; 354(9194):1940-7. PubMed ID: 10622296
[TBL] [Abstract][Full Text] [Related]
13. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.
Breuer T; Martin K; Wilhelm M; Wiesner G; Schreiber C; Hess J; Lange R; Tassani P
Eur J Cardiothorac Surg; 2009 Jan; 35(1):167-71; author reply 171. PubMed ID: 19027313
[TBL] [Abstract][Full Text] [Related]
14. Antifibrinolytics.
Schmarts
Acta Anaesthesiol Belg; 2003; 54(4):319-22. PubMed ID: 14719353
[No Abstract] [Full Text] [Related]
15. Aprotinin revisited.
Deanda A; Spiess BD
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):998-1002. PubMed ID: 22795461
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery.
Brown JR; Birkmeyer NJ; O'Connor GT
Circulation; 2007 Jun; 115(22):2801-13. PubMed ID: 17533182
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of antifibrinolytic therapy in neonatal cardiac surgery.
Lin CY; Shuhaiber JH; Loyola H; Liu H; Del Nido P; DiNardo JA; Pigula FA
PLoS One; 2015; 10(5):e0126514. PubMed ID: 25954976
[TBL] [Abstract][Full Text] [Related]
18. Lessons learned in antifibrinolytic therapy: The BART trial.
Murkin JM
Semin Cardiothorac Vasc Anesth; 2009 Jun; 13(2):127-31. PubMed ID: 19622534
[TBL] [Abstract][Full Text] [Related]
19. [Antifibrinolytic agents and repeat open-heart surgery: a comparison of tranexamic acid and low dose aprotinin].
Ait Houssa M; Selkane C; Amahzoune B; El Bekkali Y; Wahid FA; Moutaki Allah Y; Boulahya A; Ibat D; Drissi M; Azendour H; Elkirat A
Ann Cardiol Angeiol (Paris); 2007 Dec; 56(6):308-12. PubMed ID: 17976511
[TBL] [Abstract][Full Text] [Related]
20. The risks associated with aprotinin use: a retrospective study of cardiac cases in Nova Scotia.
Riddell RE; Buth KJ; Sullivan JA
Can J Anaesth; 2013 Jan; 60(1):16-23. PubMed ID: 23132043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
